期刊
FRONTIERS IN IMMUNOLOGY
卷 12, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2021.797390
关键词
COVID-19; proinflammatory cytokines; cDCs; pDCs; phosphodiesterase 4 (PDE4) inhibitors
类别
资金
- Italian Ministry of Health [COVID-2020-12371735]
- Italian Ministry of the University [MUR-PRIN 20178ALPCM_005]
- Associazione Italiana per la Ricerca sul Cancro [IG-20776]
- University of Brescia
This article reports the research results of an oral PDE4 inhibitor called Tanimilast, which can modulate the pro-inflammatory potential and Th1-polarizing potential of SCV2-RNA-induced DCs. Tanimilast did not affect the expression of maturation markers and lymph node homing receptor in DCs, but skewed towards Th2 phenotype. Both Tanimilast and the reference drug β-methasone blocked the increase of MHC-I molecules in activated DCs and restrained the proliferation and activation of cytotoxic CD8(+) T cells.
Phosphodiesterase 4 (PDE4) inhibitors are immunomodulatory drugs approved to treat diseases associated with chronic inflammatory conditions, such as COPD, psoriasis and atopic dermatitis. Tanimilast (international non-proprietary name of CHF6001) is a novel, potent and selective inhaled PDE4 inhibitor in advanced clinical development for the treatment of COPD. To begin testing its potential in limiting hyperinflammation and immune dysregulation associated to SARS-CoV-2 infection, we took advantage of an in vitro model of dendritic cell (DC) activation by SARS-CoV-2 genomic ssRNA (SCV2-RNA). In this context, Tanimilast decreased the release of pro-inflammatory cytokines (TNF-alpha and IL-6), chemokines (CCL3, CXCL9, and CXCL10) and of Th1-polarizing cytokines (IL-12, type I IFNs). In contrast to beta-methasone, a reference steroid anti-inflammatory drug, Tanimilast did not impair the acquisition of the maturation markers CD83, CD86 and MHC-II, nor that of the lymph node homing receptor CCR7. Consistent with this, Tanimilast did not reduce the capability of SCV2-RNA-stimulated DCs to activate CD4(+) T cells but skewed their polarization towards a Th2 phenotype. Both Tanimilast and beta-methasone blocked the increase of MHC-I molecules in SCV2-RNA-activated DCs and restrained the proliferation and activation of cytotoxic CD8(+) T cells. Our results indicate that Tanimilast can modulate the SCV2-RNA-induced pro-inflammatory and Th1-polarizing potential of DCs, crucial regulators of both the inflammatory and immune response. Given also the remarkable safety demonstrated by Tanimilast, up to now, in clinical studies, we propose this inhaled PDE4 inhibitor as a promising immunomodulatory drug in the scenario of COVID-19.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据